Temafloxacinum
Temafloxacinum Uses, Dosage, Side Effects, Food Interaction and all others data.
Temafloxacinum is an antibiotic agent belonging to the fluoroquinolone drug class. It was first approved for use in the U.S. market in 1992, but was withdrawn shortly due to the reports of serious adverse reactions, such as allergic reactions and hemolyric anemia, resulting in three deaths.
Temafloxacinum is a fluoroquinolone antibiotic drug, marketed as Omniflox by Abbot Laboratories, which was withdrawn from the market in 1992 due to fatal adverse effects. Flouroquinolones such as lomefloxacin possess excellent activity against gram-negative aerobic bacteria such as E.coli and Neisseria gonorrhoea as well as gram-positive bacteria including S. pneumoniae and Staphylococcus aureus. They also posses effective activity against shigella, salmonella, campylobacter, gonococcal organisms, and multi drug resistant pseudomonas and enterobacter.
| Trade Name | Temafloxacinum |
| Generic | Temafloxacin |
| Temafloxacin Other Names | Temafloxacin, Temafloxacina, Temafloxacine, Temafloxacinum |
| Type | |
| Formula | C21H18F3N3O3 |
| Weight | Average: 417.3811 Monoisotopic: 417.130026072 |
| Groups | Withdrawn |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | September 19, 2023 at 7:00 am |
Uses
For the treatment of lower respiratory tract infections, genital and urinary infections like prostatitis, and skin infections.
How Temafloxacinum works
The bactericidal action of temafloxacin results from interference with the activity of the bacterial enzymes DNA gyrase and topoisomerase IV, which are needed for the transcription and replication of bacterial DNA. DNA gyrase appears to be the primary quinolone target for gram-negative bacteria. Topoisomerase IV appears to be the preferential target in gram-positive organisms. Interference with these two topoisomerases results in strand breakage of the bacterial chromosome, supercoiling, and resealing. As a result DNA replication and transcription is inhibited.
Toxicity
Severe allergic reactions and hemolytic anemia were observed during the first few months of use leading to fatalities and the drug's eventual withdrawal from the market.
Elimination Route
Studies in healthy volunteers indicate that the average bioavailability of temafloxacin exceeds 90%, with little intersubject variability.
Half Life
Approximately 8 hours in patients with normal renal function.
Innovators Monograph
You find simplified version here Temafloxacinum
